Fusion Pharm Valuation
| FSPM Stock | USD 0.0001 0.00 0.00% |
Fusion Pharm seems to be overvalued based on Macroaxis valuation methodology. Our model computes the value of Fusion Pharm from reviewing the firm fundamentals such as Operating Margin of (1.24) %, shares outstanding of 10.59 M, and Price To Earning of (0.07) X as well as analyzing its technical indicators and probability of bankruptcy.
Enterprise Value 294.4 K | Price Sales 0.0032 |
Overvalued
Today
Please note that Fusion Pharm's price fluctuation is very steady at this time. Calculation of the real value of Fusion Pharm is based on 3 months time horizon. Increasing Fusion Pharm's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Fusion stock is determined by what a typical buyer is willing to pay for full or partial control of Fusion Pharm. Since Fusion Pharm is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Fusion Stock. However, Fusion Pharm's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.0E-4 | Real 8.4E-5 | Hype 1.0E-4 | Naive 1.0E-4 |
The intrinsic value of Fusion Pharm's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Fusion Pharm's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Fusion Pharm helps investors to forecast how Fusion stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Fusion Pharm more accurately as focusing exclusively on Fusion Pharm's fundamentals will not take into account other important factors: Fusion Pharm Cash |
|
Fusion Pharm Total Value Analysis
Fusion Pharm is currently projected to have valuation of 294.4 K with market capitalization of 1.06 K, debt of 1.2 K, and cash on hands of 1.45 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Fusion Pharm fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
294.4 K | 1.06 K | 1.2 K | 1.45 K |
Fusion Pharm Investor Information
The company recorded a loss per share of 0.15. Fusion Pharm last dividend was issued on the 27th of February 1998. The entity had 1:200 split on the 1st of March 2011. Fusion Pharm is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Fusion Pharm Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Fusion Pharm has an asset utilization ratio of 14731.03 percent. This suggests that the Company is making $147.31 for each dollar of assets. An increasing asset utilization means that Fusion Pharm is more efficient with each dollar of assets it utilizes for everyday operations.Fusion Pharm Profitability Analysis
The company reported the previous year's revenue of 594.4 K. Net Loss for the year was (42.08 K) with profit before overhead, payroll, taxes, and interest of 34.19 K.About Fusion Pharm Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Fusion Pharm. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Fusion Pharm based exclusively on its fundamental and basic technical indicators. By analyzing Fusion Pharm's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Fusion Pharm's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Fusion Pharm. We calculate exposure to Fusion Pharm's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Fusion Pharm's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 138.6 K | 145.5 K |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fusion Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Fusion Stock, please use our How to Invest in Fusion Pharm guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Consumer Staples Distribution & Retail space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fusion Pharm. If investors know Fusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fusion Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 0.133 | Return On Assets (1.38) |
The market value of Fusion Pharm is measured differently than its book value, which is the value of Fusion that is recorded on the company's balance sheet. Investors also form their own opinion of Fusion Pharm's value that differs from its market value or its book value, called intrinsic value, which is Fusion Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fusion Pharm's market value can be influenced by many factors that don't directly affect Fusion Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fusion Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fusion Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fusion Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.